SRPT Nov 2024 85.000 call
| Previous close | 55.28 |
| Open | N/A |
| Bid | 43.50 |
| Ask | 47.50 |
| Strike | 85.00 |
| Expiry date | 2024-11-15 |
| Day's range | 55.28 - 55.28 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
- Yahoo Finance Video
What next for gas prices, how the S&P 500 can reach 6,000: Market Domination
It was a quiet Friday on Wall Street, with the three major indexes (^DJI,^GSPC, ^IXIC) closing relatively flat. On the latest episode of Market Domination, Evercore ISI's Julien Emmanuel explains why he raised his year-end price target for the S&P 500 to 6,000. RBC Capital Markets US Economist Michael Reid discussed what's next for the Federal Reserve, including why he thinks the economy is in for a period of "normalization." In the latest edition of Good Buy or Goodbye, Washington Crossing Advisors Senior Portfolio Manager Chad Morganlander explains why he is buying Tractor Supply (TSCO) but skipping Macy's (M). GasBuddy's Patrick DeHaan talks about what to expect for gas prices going into the Fourth of July travel period. Yahoo Finance's Julie Hyman and Jared Blikre also recap the latest news on Sarepta Therapeutics (SRPT), Palantir (PLTR), Smith & Wesson Brands (SWBI), and McDonald's (MCD). For more expert insight and the latest market action, click here. This post was written by Stephanie Mikulich.
Investor's Business DailySarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.
Barrons.comThese Stocks Moved the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More
Nvidia tumbles after giving up its crown as the world’s most valuable company to Microsoft, Trump Media shares extend losses, Sarepta surges following expanded FDA approval for Elevidys, and Palantir’s stock is downgraded.
